Biogen exec Paul McKenzie heads to CSL as COO; Pulmatrix CEO resigns
→ After Biogen’s recent catastrophe with aducanumab, Paul McKenzie, the company’s EVP for pharmaceutical operations and technology (and member of its executive committee) …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.